Literature DB >> 24309908

PCR as a screening test for invasive aspergillosis in haematological patients: a pilot study.

Thomas Victor Maciel da Silva1, Lilian Carla Carneiro, Francine dos Santos Ramos, Ludmila Fiorenzano Baethgen, Alessandra Aparecida Paz, Daniela Zilio Larentis, Liane Esteves Daudt, Cintia Tusset, Leila Maria Lopes-Bezerra, Alessandro C Pasqualotto.   

Abstract

Invasive aspergillosis is a leading cause of morbidity and mortality in immunocompromised patients, particularly in individuals with haematological malignancy and in haematopoietic stem cell transplant recipients. Nowadays, the galactomannan (GM) assay has been widely used as an indication of invasive aspergillosis, even though the test is known to generate false-positive results. The aim of this study was to compare the performance of GM and real-time PCR (qPCR) to detected Aspergillus in blood samples obtained from high-risk haematological patients. Haematological patients were screened twice weekly with GM testing, which was performed by the Platelia ELISA kit. An additional sample of whole blood (4 ml) was obtained for the purpose of qPCR testing. Sixty-four samples from 12 patients with haematopoietic stem cell transplant or haematological malignancy were studied. The overall accordance between GM and qPCR tests was 96.9 % (62 samples). Only two samples showed contradictory results, with positive GM test and negative real-time PCR results. Based on the high concordance between GM and qPCR in terms of negative results, the main utility of qPCR could be in the confirmation of positive results seen with GM testing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24309908     DOI: 10.1007/s11046-013-9718-0

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  13 in total

1.  Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens.

Authors:  P Lewis White; Michael D Perry; Juergen Loeffler; Willem Melchers; Lena Klingspor; Stephane Bretagne; Elaine McCulloch; Manuel Cuenca-Estrella; Niklas Finnstrom; J Peter Donnelly; Rosemary A Barnes
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

2.  Aspergillus PCR: one step closer to standardization.

Authors:  P Lewis White; Stéphane Bretagne; Lena Klingspor; Willem J G Melchers; Elaine McCulloch; Bettina Schulz; Niklas Finnstrom; Carlo Mengoli; Rosemary A Barnes; J Peter Donnelly; Juergen Loeffler
Journal:  J Clin Microbiol       Date:  2010-02-10       Impact factor: 5.948

3.  Identification of Paecilomyces variotii in clinical samples and settings.

Authors:  Jos Houbraken; Paul E Verweij; Anthonius J M M Rijs; Andrew M Borman; Robert A Samson
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

4.  Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients.

Authors:  Jan Springer; C O Morton; Michael Perry; Werner J Heinz; Melinda Paholcsek; Mona Alzheimer; T R Rogers; Rosemary A Barnes; Hermann Einsele; Juergen Loeffler; P Lewis White
Journal:  J Clin Microbiol       Date:  2013-02-20       Impact factor: 5.948

5.  Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies.

Authors:  Thomas R Rogers; Charles Oliver Morton; Jan Springer; Eibhlin Conneally; Werner Heinz; Claire Kenny; Susanna Frost; Hermann Einsele; Juergen Loeffler
Journal:  Br J Haematol       Date:  2013-03-11       Impact factor: 6.998

6.  Real-time PCR on the first galactomannan-positive serum sample for diagnosing invasive aspergillosis in liver transplant recipients.

Authors:  F Botterel; C Farrugia; P Ichai; J-M Costa; F Saliba; S Bretagne
Journal:  Transpl Infect Dis       Date:  2008-07-08       Impact factor: 2.228

7.  Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis.

Authors:  Svetlana Challier; Stéphanie Boyer; Eric Abachin; Patrick Berche
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

8.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  A MIQE-compliant real-time PCR assay for Aspergillus detection.

Authors:  Gemma L Johnson; David F Bibby; Stephenie Wong; Samir G Agrawal; Stephen A Bustin
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

Review 10.  Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis.

Authors:  Valério R Aquino; Luciano Z Goldani; Alesssandro C Pasqualotto
Journal:  Mycopathologia       Date:  2007-04-05       Impact factor: 3.785

View more
  2 in total

1.  Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people.

Authors:  Mario Cruciani; Carlo Mengoli; Rosemary Barnes; J Peter Donnelly; Juergen Loeffler; Brian L Jones; Lena Klingspor; Johan Maertens; Charles O Morton; Lewis P White
Journal:  Cochrane Database Syst Rev       Date:  2019-09-03

2.  Detection of a Serum Siderophore by LC-MS/MS as a Potential Biomarker of Invasive Aspergillosis.

Authors:  Cassandra S Carroll; Lawrence N Amankwa; Linda J Pinto; Jeffrey D Fuller; Margo M Moore
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.